Thermo Fisher Scientific inked a deal with Janssen Biotech, part of Johnson & Johnson, to co-develop a companion diagnostic for cancer. The diagnostic test will support global clinical trial enrollment.
The U.S. Food and Drug Administration approved Allergan’s Durysta (bimatoprost implant) 10 mcg for intracameral administration to treat open-angle glaucoma (OAG) or ocular hypertension.
One key issue for healthcare brands that many of us know about and have seen firsthand is keeping marketing and sales teams in complete alignment as the brand message is developed and then rolled out in the field. In the race to get positive marketplace momentum going there can be a disconnect that develops in what we call the “passing of the baton” from marketing to sales. It’s when, even after all the work, time, creativity, analysis, and testing that goes into brand development, somehow a gap arises, or the timing is off as the proverbial brand “baton” is passed to the sales force.
Copenhagen-based Zealand Pharma announced a bid to buy substantially all the assets from New Jersey-based Valeritas in $23 million in cash and taking on certain liabilities.
A smart insulin device under development could revolutionize how glucose levels are monitored in diabetes patients and deliver insulin doses when necessary.
Swiss pharma giant Novartis is writing off the company’s program to develop a generic copy of GlaxoSmithKline’s blockbuster inhaler Advair.
AstraZeneca announced a bold plan to have zero carbon emissions from the company’s global operations within the next five years.
Abbott’s shares rose to an all-time high after the device maker beat Wall Street estimates for quarterly sales on higher demand for the company’s nutrition products and generic drugs.
As medical technology increases, so too does the availability of options for different biomedical applications.
Some analysts are checking their crystal balls to get an idea if 2020 will be a busy year for investors, and the early thinking on biotech is yes.